Patents by Inventor David Gong

David Gong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10381875
    Abstract: A method and system for providing wireless power transfer through a metal object is provided. In one aspect, an apparatus for wirelessly receiving power via a magnetic field is provided. The apparatus includes a metal cover including an inner portion and an outer portion. The outer portion is configured to form a loop around the inner portion of the metal cover. The outer portion is configured to inductively couple power via the magnetic field. The apparatus includes a receive circuit electrically coupled to the outer portion and configured to receive a current from the outer portion generated in response to the magnetic field. The receive circuit is configured to charge or power a load based on the current.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 13, 2019
    Assignee: QUALCOMM Incorporated
    Inventors: Seong Heon Jeong, Mei-Li Chi, Curtis Gong, David George Fern, Francesco Carobolante
  • Publication number: 20190218212
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 18, 2019
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Publication number: 20190216062
    Abstract: A non-human animal model for neurodegenerative and/or inflammatory diseases is provided, which non-human animal comprises a disruption in a C9ORF72 locus. In particular, non-human animals described herein comprise a deletion of an entire coding sequence of a C9ORF72 locus. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)), autoimmune and/or inflammatory diseases (e.g., SLE, glomerulonephritis) are also provided.
    Type: Application
    Filed: March 27, 2019
    Publication date: July 18, 2019
    Inventors: Amanda Atanasio, Burcin Ikiz, Guochun Gong, Michael L. Lacroix-Fralish, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 10351922
    Abstract: Alloys, a process for preparing the alloys, and manufactured articles including the alloys are described herein. The alloys include, by weight, about 11.5% to about 14.5% chromium, about 0.01% to about 3.0% nickel, about 0.1% to about 1.0% copper, about 0.1% to about 0.2% carbon, about 0.01% to about 0.1% niobium, 0% to about 5% cobalt, 0% to about 3.0% molybdenum, and 0% to about 0.5% titanium, the balance essentially iron and incidental elements and impurities.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: July 16, 2019
    Assignee: QuesTek Innovations LLC
    Inventors: David R. Snyder, Jiadong Gong, Jason T. Sebastian, James A. Wright, Herng-Jeng Jou, Zechariah Feinberg
  • Patent number: 10351921
    Abstract: A martensitic stainless steel alloy is strengthened by copper-nucleated nitride precipitates. The alloy includes, in combination by weight percent, about 10.0 to about 12.5 Cr, about 2.0 to about 7.5 Ni, up to about 17.0 Co, about 0.6 to about 1.5 Mo, about 0.5 to about 2.3 Cu, up to about 0.6 Mn, up to about 0.4 Si, about 0.05 to about 0.15 V, up to about 0.10 N, up to about 0.035 C, up to about 0.01 W, and the balance Fe and incidental elements and impurities. The nitride precipitates may be enriched by one or more transition metals. A case hardened, corrosion resistant variant has a reduced weight percent of Ni, enabling increased use of Cr, and decreased Co.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 16, 2019
    Assignee: QuesTek Innovations LLC
    Inventors: David R. Snyder, Jiadong Gong, Jason T. Sebastian, James A. Wright, Herng-Jeng Jou, Zechariah Feinberg
  • Patent number: 10308554
    Abstract: The concrete composition includes, in a mixture with water, a hydraulic binder, sand and aggregates, wherein the hydraulic binder includes a Portland cement of high reactivity, and the hydraulic binder is present in an amount of 280-340 kg per cubic meter of concrete, a shrinkage reducing admixture is present in an amount of 0-4 L per cubic meter of concrete, and water is present in an amount of 140-160 L per cubic meter of concrete.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 4, 2019
    Assignee: Holcim Technology Ltd.
    Inventors: David Babayan, Moussa Baalbaki, Bill Gong
  • Patent number: 10296602
    Abstract: Methods, apparatus, systems, and computer-readable media for assigning a real-time clock domain timestamp to sensor frames from a sensor component that operates in a non-real-time time-domain. In some implementations, a real-time component receives capture instances that each indicate capturing of a corresponding sensor data frame by the sensor component. In response to a capture output instance, the real-time component or an additional real-time component assigns a real-time timestamp to the capture output instance, where the real-time timestamp is based on the real-time clock domain. Separately, a non-real-time component receives the corresponding sensor data frames captured by the sensor component, along with corresponding metadata. For each sensor data frame, it is determined whether there is a real-time timestamp that corresponds to the data frame and, if so, the real-time timestamp is assigned to the sensor data frame.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: May 21, 2019
    Assignee: X DEVELOPMENT LLC
    Inventors: Emily Cooper, Matthieu Guilbert, Thomas Buschmann, David Deephanphongs, Yuanzheng Gong
  • Patent number: 10285388
    Abstract: A non-human animal model for neurodegenerative and/or inflammatory diseases is provided, which non-human animal comprises a disruption in a C9ORF72 locus. In particular, non-human animals described herein comprise a deletion of an entire coding sequence of a C9ORF72 locus. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)), autoimmune and/or inflammatory diseases (e.g., SLE, glomerulonephritis) are also provided.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 14, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Amanda Atanasio, Burcin Ikiz, Guochun Gong, Michael L. Lacroix-Fralish, Ka-man Venus Lai, David M. Valenzuela
  • Publication number: 20190136201
    Abstract: The invention provides stem cell derived beta-pancreatic cells and animal models of T2D in which cells have been grafted. The stem cells bear a mutated form of SLC30A8 conferring protection or susceptibility to T2D. The cells and animal models can be used for drug screening as well as to provide insights into the mechanism of T2D and potentially new therapeutic and diagnostic targets.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 9, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Guochun Gong, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 7767198
    Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: August 3, 2010
    Assignee: Novartis AG
    Inventors: Jayne E. Hastedt, Kirsten M. Cabot, David Gong, Dennis M. Hester
  • Publication number: 20070122354
    Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
    Type: Application
    Filed: December 22, 2006
    Publication date: May 31, 2007
    Inventors: Jayne Hastedt, Kirsten Cabot, David Gong, Dennis Hester
  • Patent number: 7172768
    Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: February 6, 2007
    Assignee: Nektar Therapeutics
    Inventors: Jayne Hastedt, Kirsten Cabot, David Gong, Dennis Hester
  • Publication number: 20050186146
    Abstract: A powder includes IL-13 antagonist, wherein the powder has a mass median aerodynamic diameter (MMAD) of less than about 10 ?m. A composition includes a spray-dried particle including IL-13 antagonist. A method of administering IL-13 antagonist to the lungs of a subject includes: dispersing a dry powder composition involving IL-13 antagonist to form an aerosol; and delivering the aerosol to the lungs of the subject by inhalation of the aerosol by the subject, thereby ensuring delivery of the IL-13 antagonist to the lungs of the subject. A method of treating an IL-13-related condition includes: pulmonarily administering a therapeutically effective amount of a dry powder including IL-13 antagonist. A method of preparing IL-13 antagonist-containing powder involves: combining IL-13 antagonist, optional excipient, and solvent to form a mixture or solution; and spray drying the mixture or solution to obtain the powder.
    Type: Application
    Filed: February 14, 2005
    Publication date: August 25, 2005
    Applicant: Nektar Therapeutics
    Inventors: David Gong, Jayne Hastedt, John Patton
  • Publication number: 20050186143
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 ?-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Application
    Filed: November 17, 2004
    Publication date: August 25, 2005
    Applicant: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne Hastedt, S. Lehrman, Hi-Shi Chiang, David Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Publication number: 20050129625
    Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
    Type: Application
    Filed: February 1, 2005
    Publication date: June 16, 2005
    Inventors: Jayne Hastedt, Kirsten Cabot, David Gong, Dennis Hester
  • Publication number: 20050008580
    Abstract: Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 ?m or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.
    Type: Application
    Filed: April 8, 2004
    Publication date: January 13, 2005
    Applicants: Wyeth, Nektar Therapeutics
    Inventors: David Gong, Jayne Hastedt, Robert Schaub, Nicholas Warne, Andrew Dorner, Chandra Webb, James Keith
  • Patent number: 6838075
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 ?-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: January 4, 2005
    Assignee: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Publication number: 20030190291
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Application
    Filed: March 14, 2003
    Publication date: October 9, 2003
    Applicant: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Patent number: 6569406
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: May 27, 2003
    Assignee: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Publication number: 20020065399
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Application
    Filed: August 7, 2001
    Publication date: May 30, 2002
    Applicant: Inhale Therapeutic Systems, Inc.
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot